Latest Tenofovir Stories
In the heart of the global AIDS epidemic, a breakthrough has been discovered in preventing the HIV virus from being transmitted among heterosexual couples.
In a result that will fundamentally change approaches to HIV prevention in Africa, an international study has demonstrated that individuals at high risk for HIV infection who took a daily tablet containing an HIV medication â€“ either the antiretroviral medication tenofovir or tenofovir in combination with emtricitabine â€“ experienced significantly fewer HIV infections than those who received a placebo pill.
Today, researchers from two major HIV prevention trials announced favorable results of an approach called oral pre-exposure prophylaxis, or PrEP.
NEW YORK, July 13, 2011 /PRNewswire-USNewswire/ -- Results from two African studies of pre-exposure prophylaxis, or PrEP, released today provide clear evidence that the antiretroviral drugs used to treat HIV can also be used to prevent HIV among heterosexual men and women at risk of HIV infection.
PITTSBURGH and HYDERABAD, India, July 12, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced an expanded licensing agreement between Gilead Sciences Inc. and Mylan's Matrix Laboratories Limited.
TITUSVILLE, N.J., May 20, 2011 /PRNewswire/ -- The US Food and Drug Administration (FDA) today approved EDURANT(TM) (rilpivirine) tablets for use in combination with other antiretroviral agents (ARVs) in the treatment of human immunodeficiency virus type 1 (HIV-1) in adults who have never taken HIV therapy (treatment-naive).
A new study from the University of North Carolina at Chapel Hill School of Medicine further validates the use of humanized BLT mice in the fight to block HIV transmission.
An HIV-positive person who takes anti-retroviral drugs immediately after diagnosis, rather than waiting until their health begins to decline, can reduce the risk of spreading the virus to uninfected partners by 96%.
Researchers are stopping tests of a daily pill to prevent infection with the AIDS virus in thousands of African women.
The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis (PrEP) can be implemented on a large scale.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.